An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC) Meeting Abstract
| Authors: | Dsouza, N.; Gaffney, C.; Hernandez, C.; Moran, P.; Worth, K.; McCarter, M.; de Jesus, M. R.; Solit, D. B.; Sarungbam, J.; Al-Ahmadie, H. A.; Bochner, B. H.; Iyer, G.; Rosenberg, J. E.; Pietzak, E. J. |
| Abstract Title: | An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS4614 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS4614 |
Altmetric
Citation Impact
BMJ Impact Analytics
